Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization. Intellia is a clinical-stage gene editing company ...

As part of this portfolio reorganization, NTLA is planning to prioritize the development of its investigational in vivo genome-editing candidate, Nexiguran ziclumeran (nex-z, also known as NTLA ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

AdvisorNet Financial Inc grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 96.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,085 shares of the company ...

Intellia faces backlash after halting drug work and layoffs, despite strategic decisions to focus on best ideas. Click here to find out why NTLA is a Sell.

NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its target price decreased by stock analysts at Oppenheimer from $60.00 to $40.00 in a research report issued on Monday,Benzinga reports.

NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...